Abivax doubles on HIV reservoir readout

Abivax S.A.S. (Euronext:ABVX) rose €10.50 (114%) to €19.70 after it said results of a Phase IIa study showed ABX464 reduced HIV reservoirs in chronically infected HIV patients.The small molecule inhibits viral replication by preventing rev-mediated export of unspliced HIV-1 mRNA transcripts to the cytoplasm.

The ABX464-004 study enrolled 30 chronically infected HIV patients in Spain, Belgium, and France. Abivax said seven of 14 evaluable patients had reductions of viral reservoirs at day 28, with a mean reduction of 40%, compared with no responders among four evaluable patients receiving placebo. The study measured total HIV DNA detected in peripheral blood mononuclear cells (PBMCs), a validated biomarker of viral reservoir load...